{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:13:59Z","timestamp":1778897639645,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103268","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:28:04Z","timestamp":1763648884000},"page":"103268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer\u2014a systematic review and meta-analysis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-9701","authenticated-orcid":false,"given":"Vasiliki","family":"Xirou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Fernanda Albuja","family":"Altamirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishabh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gusdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Barnum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"McNichol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thita","family":"Chiasakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8426-3398","authenticated-orcid":false,"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103268_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2025.103268_bib2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103268_bib3","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","article-title":"Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer","volume":"164","author":"Lyman","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103268_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103268_bib5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2025.103268_bib6","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103268_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103268_bib8","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2025.103268_bib9","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2025.103268_bib10","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2025.103268_bib11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103268_bib12","first-page":"1203","article-title":"How to choose an appropriate anticoagulant for cancer-associated thrombosis","volume":"19","author":"Schaefer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2025.103268_bib13","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1002\/onco.13584","article-title":"Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats","volume":"26","author":"O\u2019Connell","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.rpth.2025.103268_bib14","article-title":"How I treat cancer-associated thrombosis","volume":"5","author":"Moik","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.rpth.2025.103268_bib15","first-page":"1217","article-title":"A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases","volume":"33","author":"Brown","year":"1973","journal-title":"Cancer Res"},{"key":"10.1016\/j.rpth.2025.103268_bib16","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJM200006293422604","article-title":"Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism","volume":"342","author":"Schulman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103268_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103268_bib18","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103268_bib19","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2025.103268_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.rpth.2025.103268_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2288-4-17","article-title":"Meta-analytic methods for pooling rates when follow-up duration varies: a case study","volume":"4","author":"Guevara","year":"2004","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.rpth.2025.103268_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2023.05.012","article-title":"Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis","volume":"227","author":"Wang","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103268_bib23","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jtha.2024.03.021","article-title":"A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: communication from the ISTH SSC subcommittee on hemostasis and malignancy","volume":"22","author":"Bindal","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103268_bib24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1078155217718382","article-title":"Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: the Re-CLOT study","volume":"24","author":"Alzghari","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.rpth.2025.103268_bib25","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/jth.15519","article-title":"Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103268_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004012","article-title":"Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: a population-based cohort study","volume":"19","author":"Khan","year":"2022","journal-title":"PLoS Med"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2025.103268_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2023-187297","article-title":"Overall survival of warfarin compared to LMWH\/DOACs in cancer-associated venous thromboembolism: VA cohort study","volume":"142","author":"Ryu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103268_bib28","first-page":"877","article-title":"Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer","volume":"30","author":"Kinnunen","year":"2019","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.rpth.2025.103268_bib29","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1160\/TH-17-06-0382","article-title":"Vitamin K antagonists compared to low-molecular-weight heparins for treatment of cancer-associated venous thromboembolism: an observational study in routine clinical practice","volume":"117","author":"den Exter","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103268_bib30","first-page":"2041","article-title":"Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients","volume":"10","author":"Amato","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.rpth.2025.103268_bib31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rpth.2025.103268_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2025.103268_bib33","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2025.103268_bib34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism\u2014analysis of the CATCH study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103268_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.rpth.2025.103268_bib36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.molmed.2022.07.002","article-title":"New insights into vitamin K biology with relevance to cancer","volume":"28","author":"Welsh","year":"2022","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.rpth.2025.103268_bib37","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.thromres.2021.11.004","article-title":"The impact of warfarin on overall survival in cancer patients","volume":"213","author":"Chiasakul","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103268_bib38","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.18632\/oncotarget.2422","article-title":"Axl as a mediator of cellular growth and survival","volume":"5","author":"Axelrod","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.rpth.2025.103268_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cancers8110103","article-title":"The receptor tyrosine kinase AXL in cancer progression","volume":"8","author":"Rankin","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rpth.2025.103268_bib40","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/cancers12071850","article-title":"Gas6\/Axl signaling pathway in the tumor immune microenvironment","volume":"12","author":"Tanaka","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.rpth.2025.103268_bib41","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.18632\/oncotarget.26882","article-title":"Axl signaling is an important mediator of tumor angiogenesis","volume":"10","author":"Tanaka","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.rpth.2025.103268_bib42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/1078-0432.CCR-07-0862","article-title":"Axl and growth arrest\u2013specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme","volume":"14","author":"Hutterer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rpth.2025.103268_bib43","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1593\/neo.05640","article-title":"Expression of Axl in lung adenocarcinoma and correlation with tumor progression","volume":"7","author":"Shinh","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.rpth.2025.103268_bib44","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-08-2514","article-title":"Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival","volume":"15","author":"Gustafsson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rpth.2025.103268_bib45","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1541-7786.MCR-20-0860","article-title":"AXL is a key factor for cell plasticity and promotes metastasis in pancreatic cancer","volume":"19","author":"Du","year":"2021","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.rpth.2025.103268_bib46","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-14-2887-T","article-title":"Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis","volume":"75","author":"Kirane","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.rpth.2025.103268_bib47","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature12998","article-title":"The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells","volume":"507","author":"Paolino","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.rpth.2025.103268_bib48","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"2023","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:54:40Z","timestamp":1778896480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925005928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037925005928"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103268","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer\u2014a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103268"}}